Evidence map›Paper›PMID 34275349›Full record

Trial reportDiabetes & vascular disease research

The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study.

Kwok-Leung Ong, Liang Wu, Andrzej S Januszewski, Rachel O'Connell, Aimin Xu, Russell S Scott, David R Sullivan, Kerry-Anne Rye, Huating Li, Ronald Cw Ma and 5 more

Open access · diamondAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes & vascular disease research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 4 countries.

Kwok-Leung OngNHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.ORCID 0000-0001-7229-7614
Liang WuNHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
Andrzej S JanuszewskiNHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
Rachel O'ConnellNHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
Aimin XuDepartment of Medicine, University of Hong Kong, Hong Kong, China.
Russell S ScottLipid and Diabetes Research Group, Christchurch Hospital, Christchurch, New Zealand.
David R SullivanNHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
Kerry-Anne RyeLipid Research Group, School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia.
Huating LiDepartment of Endocrinology and Metabolism, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Clinical Center of Diabetes, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Ronald Cw MaDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
Liping LiNHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
Val GebskiNHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
Alicia J JenkinsNHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
Weiping JiaDepartment of Endocrinology and Metabolism, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Clinical Center of Diabetes, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Anthony C KeechNHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
The University of Sydney · AUShanghai Jiao Tong University · CNChinese University of Hong Kong · HKChristchurch Hospital · NZUniversity of Hong Kong · HKUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNeutrophil elastase (NE) and proteinase 3 (PR3) are novel inflammation biomarkers. We investigated their associations with chronic complications, determinants of biomarker levels and effects of fenofibrate in patients with type 2 diabetes mellitus (T2DM) from Fenofibrate Intervention and Event Lowering in Diabetes study.

methodsPlasma NE and PR3 levels were quantified at baseline (

resultsHigher waist-to-hip ratio, homocysteine and C-reactive protein and lower apoA-II were determinants of higher NE and PR3 levels. Higher NE levels were associated with on-trial stroke and cardiovascular mortality, and higher PR3 levels with on-trial stroke, but associations were not significant after adjustment for confounding factors. Although higher NE and PR3 levels were associated with baseline total microvascular disease, only NE levels were associated with on-trial neuropathy or amputation. These associations were not significant after adjusting for multiple comparisons. NE and PR3 levels did not change with fenofibrate.

conclusionsIn T2DM plasma NE and PR3 levels are associated with vascular risk factors, and total microvascular disease at baseline, but on rigorous analyses were not associated with on-trial complications. Levels were not changed by fenofibrate.

Indexed as

AgedBiomarkersDiabetes Mellitus, Type 2FemaleFenofibrateHumansHypolipidemic AgentsInflammation MediatorsLeukocyte ElastaseLipidsMaleMiddle AgedMyeloblastinTime FactorsTreatment OutcomeBiomarkersELANE protein, humanFenofibrateHypolipidemic AgentsInflammation MediatorsLeukocyte ElastaseLipidsMyeloblastinCardiovascular diseasediabetesmicrovascular diseaseneutrophil elastaseproteinase 3serine protease

Identifiers

PMID34275349
PMCPMC8481737
OpenAlexW3184681845

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.